10-Q: Longeveron Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Sentiment:

Quarterly Report 14 August 2024 4:05 PM

Longeveron Inc. reports a reduced net loss and increased revenue for the second quarter of 2024, driven by clinical trial and contract manufacturing revenue, while also securing significant funding through warrant exercises and a direct offering.

Delay expectedThe company discontinued its clinical trial in Japan to evaluate Lomecel-B for Aging-related Frailty.

Capital raiseThe company completed a public offering in April 2024, raising $4.7 million net.The company completed warrant exercises in April and June 2024, raising $5.6 million and $4.4 million respectively.Subsequent to the quarter end, in July 2024, the company raised an additional $6.2 million from warrant exercises and $9.0 million from a registered direct offering and concurrent private placement.

Better than expectedThe company's net loss decreased significantly compared to the same period last year.The company's revenue increased substantially year-over-year.The company secured significant funding through multiple financing activities.

Summary

Longeveron Inc., a clinical-stage biotechnology company, released its financial results for the quarter ended June 30, 2024.
The company reported a net loss of $3.4 million for the quarter, a significant improvement compared to the $5.6 million loss in the same period of 2023.
Revenue increased to $0.5 million, up from $0.2 million in the second quarter of 2023, primarily due to increased clinical trial revenue from the Bahamas Registry Trial and new contract manufacturing revenue.
Operating expenses decreased to $3.8 million from $5.8 million year-over-year, driven by reduced general and administrative and research and development costs.
The company's cash and cash equivalents stood at $12.4 million as of June 30, 2024.
Longeveron believes its current cash, along with $15.3 million in gross proceeds from July 2024 financing, will fund operations through the fourth quarter of 2025.
The company completed a public offering in April 2024, raising $4.7 million net, and warrant exercises in April and June 2024, raising $5.6 million and $4.4 million respectively.
Subsequent to the quarter end, in July 2024, the company raised an additional $6.2 million from warrant exercises and $9.0 million from a registered direct offering and concurrent private placement.
The company is focused on developing Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS) and Alzheimers disease (AD), and has discontinued its clinical trial in Japan for Aging-related Frailty.

Sentiment

Score: 7

Explanation: The document shows a positive trend with reduced losses, increased revenue, and successful capital raises. However, the company is still in a high-risk phase with no approved products and reliance on future funding. The RMAT and Fast Track designations are very positive.

Positives

The company has significantly reduced its net loss compared to the same period last year.
Revenue has more than doubled year-over-year, indicating growing demand for its clinical trials and manufacturing services.
Operating expenses have decreased substantially, reflecting cost-saving measures.
The company has successfully raised significant capital through multiple financing activities.
Lomecel-B has received RMAT and Fast Track designations from the FDA for Alzheimers disease, which could expedite the approval process.
The Phase 2a trial for Alzheimers disease showed promising results, including a slowing of disease progression and preservation of brain volumes.
The Phase 2b trial for HLHS is progressing well with over 70% enrollment.
The company has a strong cash position, which is expected to fund operations through the fourth quarter of 2025.

Negatives

The company continues to incur operating losses and has an accumulated deficit of $101 million.
The company is dependent on raising additional capital to fund its operations.
The company has discontinued its clinical trial in Japan for Aging-related Frailty.
The company has no approved products and has only generated revenue from grants, clinical trials, and contract manufacturing.
The company is subject to risks and uncertainties associated with research, development, and commercialization of its product candidates.

Risks

The company's future operations are dependent on the success of its efforts to raise additional capital.
There is no assurance that the company's research and development will be successfully completed or that any products developed will obtain necessary government regulatory approval.
The company operates in a highly competitive and rapidly changing environment.
The company is dependent on the services of its employees, partners, and consultants.
The company may face difficulties in obtaining access to capital, which could dilute investor ownership.
The company's ability to remain listed on the Nasdaq Capital Market is not guaranteed.
The company's clinical trials may not demonstrate the safety and efficacy of its product candidates.
The company may not be able to obtain or protect its intellectual property rights.
The company may need to hire additional personnel and may not be able to attract and retain such personnel.

Future Outlook

The company believes its current cash and cash equivalents, along with $15.3 million in gross proceeds from July 2024 financing transactions, will enable it to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2025. The company is actively seeking financing opportunities to extend its cash runway while taking measures to reduce cash expenditures.

Management Comments

Management believes that the company's existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2025.
Management is actively seeking financing opportunities to extend the company's cash runway while taking measures to reduce cash expenditures.
Management is focused on the company's primary strategic program in HLHS.

Industry Context

The company is operating in the competitive and rapidly evolving regenerative medicine and biotechnology industry. The company's focus on cell-based therapies for aging-related and life-threatening conditions aligns with broader industry trends towards innovative treatments for unmet medical needs. The company's receipt of RMAT and Fast Track designations for Alzheimers disease reflects the growing interest in developing effective therapies for this condition.

Comparison to Industry Standards

Longeveron's focus on regenerative medicine and cell therapies places it in a competitive landscape with companies like Mesoblast, Athersys, and BioTime, all of which are developing cell-based therapies for various indications.
The company's reported net loss of $3.4 million for the quarter is relatively high compared to some established biotech companies, but is typical for a clinical-stage company with ongoing research and development expenses.
The company's revenue of $0.5 million for the quarter is modest compared to companies with commercialized products, but is consistent with a company primarily focused on clinical trials and research.
The company's cash position of $12.4 million, combined with the $15.3 million raised in July, provides a runway that is comparable to other companies at a similar stage of development.
The company's receipt of RMAT and Fast Track designations for Alzheimers disease is a positive development that could accelerate the approval process, similar to other companies that have received these designations for their therapies.
The company's Phase 2b trial for HLHS is a significant step towards potential commercialization, similar to other companies that have advanced their therapies through clinical trials.

Related Party Transactions

The company has a consulting services agreement with its CSO, Dr. Joshua Hare, and a license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC.

Stakeholder Impact

Shareholders will be impacted by the dilution from the recent capital raises, but also by the potential for future growth and success of the company's clinical programs.
Employees may be impacted by the company's cost-saving measures, including staff reductions.
Patients with HLHS and Alzheimers disease may benefit from the company's development of Lomecel-B.
The company's suppliers and partners may be impacted by the company's financial performance and strategic decisions.

Next Steps

Continue the Phase 2b clinical trial for HLHS (ELPIS II).
Analyze data from the Phase 2a trial for Alzheimers disease (CLEAR MIND).
Seek strategic collaborations and partnerships for Lomecel-B in Alzheimers disease.
Expand manufacturing capabilities to commercial-scale production.
Explore potential additions to the product pipeline through internal research and development and in-licensing.
Continue to expand the intellectual property portfolio.
Continue to enroll patients on the Frailty and Cognitive Impairment registry trials in The Bahamas and launch an Osteoarthritis registry trial.

Key Dates

Date	Description
October 9, 2014	Longeveron was formed as a Delaware limited liability company.
December 15, 2014	Longeveron was authorized to transact business in Florida.
November 20, 2014	The company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its CSO.
November 20, 2014	The company entered into an Exclusive License Agreement with UM for the use of certain Aging-related Frailty Mesenchymal Stem Cell (MSC) technology rights.
March 27, 2015	The company entered into a technology services agreement with Optimal Networks, Inc.
December 22, 2016	The company entered into an exclusive license agreement with JMH MD Holdings, LLC for the use of CD271 cellular therapy technology.
February 12, 2021	Longeveron, LLC converted its corporate form to a Delaware corporation, Longeveron Inc.
August 12, 2021	The underwriter warrants from the IPO became exercisable.
November 8, 2021	Lomecel-B received Rare Pediatric Disease (RPD) Designation for HLHS.
December 2, 2021	Lomecel-B received Orphan Drug Designation (ODD) for HLHS.
August 24, 2022	Lomecel-B received Fast Track Designation for HLHS.
November 16, 2022	The company accounted for but had not issued 4,814 RSUs convertible to unregistered shares of Class A common stock, with an aggregate value of $0.2 million as payment for accrued expenses under the consulting agreement with the CSO.
April 14, 2023	The technology services agreement with Optimal Networks, Inc. was terminated.
May 24, 2023	The 4,814 RSUs convertible to unregistered shares of Class A common stock were issued to the CSO.
August 16, 2023	The company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants.
September 2023	The company completed its Phase 2a AD clinical trial, known as the CLEAR MIND trial.
November 2023	Longeveron received notice from the World Health Organization (WHO) that laromestrocel has been selected as the proposed International Nonproprietary Name for Longeverons Lomecel-B product.
March 26, 2024	The company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a one-for-10 (1:10) basis.
April 8, 2024	The company commenced a public offering of Class A common stock and pre-funded warrants.
April 10, 2024	The public offering closed.
April 16, 2024	The company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants.
April 18, 2024	The inducement transaction closed.
June 17, 2024	The company entered into additional inducement letter agreements with the holders of its existing Series D Warrants.
June 30, 2024	End of the reporting period for the quarterly report.
July 9, 2024	The FDA granted Regenerative Medicine Advanced Therapeutics (RMAT) Designation to Lomecel-B for the treatment of mild Alzheimers Disease.
July 10, 2024	A holder exercised Series C warrants for 50,000 shares of Class A common stock for cash.
July 10, 2024	Certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of 150,000 shares of Class A common stock for cash.
July 17, 2024	The FDA granted Fast Track designation to Lomecel-B for the treatment of mild Alzheimers Disease.
July 17, 2024	The company issued to the placement agent warrants to purchase up to 10,500 shares of Class A common stock.
July 17, 2024	A holder of the June private placement warrants exercised the same to purchase 2,319,186 shares of Class A common stock for cash.
July 18, 2024	The company entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of 2,236,026 shares of our Class A common stock.
July 18, 2024	The company entered into an additional Exclusive License Agreement with UM for technology rights developed by our CSO at UM.
July 19, 2024	The unregistered July private placement warrants became exercisable.
July 24, 2024	The company issued to the placement agent warrants to purchase up to 162,344 shares of Class A common stock.
August 6, 2024	The company filed a registration statement with the SEC on Form S-1 registering the resale of an aggregate of 2,565,392 shares of Class A common stock issuable upon exercise of certain warrants.
August 12, 2024	The Form S-1 was declared effective by the SEC.
August 14, 2024	The date of the quarterly report.

Keywords

Lomecel-B, Hypoplastic Left Heart Syndrome, Alzheimers disease, Regenerative Medicine, Clinical Trials, Biotechnology, Cell Therapy, RMAT Designation, Fast Track Designation, Financial Results, Warrant Exercise, Public Offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.